Abstract. Compatible with the epidemiology and natural history of cervical cancer and with experimental findings that HPV-immortalized nontumorigenic cells are similar to cervical carcinoma cells, in terms of the quantity and type of viral RNA expressed, it is believed that additional cellular genetic events are necessary for tumorigenic conversion. In the current study we detected codon 12 point mutations of the K-ras oncogene with an incidence of 28.2% in malignant lesions of the cervix, as well as HPV 18 at a higher rate than HPV16 (30.2% vs 27.9%) in genital lesions, by PCR and RFLP analysis. Codon 12 point mutations of K-, H-and Nras were also found in benign lesions of the cervix, in endometrial and in ovarian carcinomas, although at a lower frequency. It is suggested that the mutationally activated ras oncogenes cooperate with HPV in the early stages of carcinogenesis of the human female reproductive tract.
Introduction
Human papilloma viruses (HPVs) are strongly implicated in the genesis of human cervical carcinoma, anal squamous cell carcinoma, squamous cell carcinoma of the skin and isolated cases of squamous cell carcinoma of the upper respiratory tract (1, 2) . At least 24 of more than 65 genotypes of HPV are associated with anogenital lesions and they can be subdivided into two groups, the 'low risk' HPVs such as HPV6 and HPV11 and the 'high risk' HPVs such as HPV 16 and HPV 18. HPV DNA has been identified in precancerous and neoplastic lesions of the uterine cervix in over 84% of patients examined (3) .
At least two early genes, E6 and E7, are consistently expressed in HPV-associated cervical cancers and their derived cell lines. E6 and E7 genes bind to the cellular p53 and Rb tumor suppressor proteins, respectively (4) (5) (6) and are sufficient for in vitro cellular immortalization (7, 8) . In contrast to fully transformed cervical carcinoma cells, HPVimmortalized keratinocytes are nontumorigenic in nude mice (9) .
As is the case for other DNA tumor viruses, the development of HPV-associated cancer is presumed to be a multistep process. Since HPV 16 and HPV 18 are able to immortalize primary keratinocytes, but they are not sufficient, except in rare cases, to engender a full tumorigenic conversion (10) , it has been suggested that activation of cellular oncogenes is necessary for the progression of cervical cancer. Activation of c-myc and Η-ras appears to be quite common in cervical cancers, and overexpression of cmyc is associated with poor prognosis (11, 12) . Furthermore, it has been demonstrated that a ras gene can induce tumorigenic conversion of HPV-immortalized cervical keratinocytes (13, 14) indicating a cooperative effect between the ras and E6/E7 genes in cellular transformation.
Additionally, the observation that overexpression of HPV 18 E6, c-myc or activated Η-ras can partially overcome the growth inhibitory effect of wild-type p53 in NIH3T3 cells, suggests that the cooperation between HPV E6 and these cellular oncogenes is necessary to completely overcome the anti-oncogenic reaction of p53 in the development of these tumors (15) . It has also been demonstrated that the rapid ubiquitin-dependent degradation of p53 through the E6-E6 associated protein complex (E6-E6-AP) requires additional cellular factors, present only in specific tissues or at certain phases during cell growth or differentiation (16) .
Alterations in fos expression, which appear to be an important facet of epidermal differentiation in vivo, could also contribute to the malignant progression of HPV immortalized cells (17) .
Activated ras genes by point mutations have been reported in cervical cancer, although at low frequency (18) , while in endometrial carcinomas the frequency was significantly higher (18) (19) (20) . Mutations of K-ras oncogene have also been reported in human mucinous ovarian tumors (21) .
In the current study the presence of codon 12 point mutations of K-, H-and N-ras genes, as well as detection and typing of the human papillomavirus was examined in 112 Oligonucleotide primers and PCR amplification. The oligonucleotides used for K-ras and Η-ras codon 12 have been previously described (22) . For N-ras codon 12 we used the oligonucleotides: NA12: 5' AACTGGTGGTGGT TGGAGCC 3' and NB12: 5' CTCTATGGTGGGATCA TATT 3' (Fig. 1) . For the detection and distinction of the HPV the general primers GP5 and GP6 (23) Each cycle included a denaturation step at 94°C for 1 min, an annealing step at 58°C for 45 sec and an elongation step at 72°C for 25 sec, increasing the elongation time 1 sec per cycle.
HPV amplification. The reaction solution, using the general primers GP5 and GP6, contained 20 mM (NH 4 ) 2 S0 4 , 2.5 mM MgCl,, 75 mM Tris-HCl pH 9.0, 0.01% (w/v) Tween, 200 μΜ of each dNTP, 0.75 μΜ of each primer and 1.25 U Taq polymerase. The mixture was heated for 1 min at 95°C, and then subjected to 40 cycles of amplification. Each cycle included a denaturation step at 94°C for 50 sec, an annealing step at 52°C for 50 sec and an elongation step at 72°C for 45 sec, increasing the elongation time 1 sec per cycle.
Multiplex PCR was employed for the distinction of HPV types, where four pairs of primers were used stimultaneously (for HPV types 11, 16, 18 and 33), with each virus type giving different length of amplified DNA. The reaction solution, using the specific set of primers contained 20 mM (NH 4 ) 2 S0 4 , 2.5 mM MgCl,, 75 mM Tris-HCl pH 9.0, 0.01% (w/v) Tween, 250 μΜ of each dNTP, 0.5 μΜ of each primer and 1.25 U Taq polymerase. The mixture was heated for 1 min at 95°C, and then subjected to 35 cycles of amplification. Each cycle included a denaturation step at 94°C for 1 min, an annealing step at 56°C for 50 sec and an elongation step at 72°C for 50 sec, increasing the elongation time 1 sec per cycle. To establish type specificity of primer-directed ampification, each set of primers was tested with template Plasmid DNA of the five HPV types 6b, 11, 16, 18 and 33.
RFLP analysis. K-ras: 10-20 μΐ aliquots of the amplification products were digested for 3 h with 40 U BstNI.
H-ras or Ν-ras. 10-20 μΐ aliquots of the amplification products were digested O/N with 40 U Mspl. Digestion products were electrophoresed through an 8% Polyacrylamide gel, or a 4% agarose gel.
HPV-general primers. The type distinction using the specific primers was reconfirmed with digestion of the amplification products, using the general primers, with 50 U of Rsal giving a different pattern for each type. Digestion products were electrophoresed through a 10% Polyacrylamide gel. As control the amplified product of plasmid DNA of the HPV types 6b, 11, 16, 18 and 33 were used.
Gels were stained with ethidium bromide and photographed on a UV light transilluminator. Enzymes were supplied by New England Biolabs and the conditions followed for digestions were those recommended by the supplier. Incubation temperatures were 60°C for BstNI and 37°C for Mspl and Rsal.
Statistical analysis. Statistical analysis was performed on a Macintosh computer with the help of STATWORK (version 1.2) software.
Results
After reviewing the selected tissue sections of 112 samples, the histological diagnosis, tumor classification and differentiation was as follows: There were 37 cases of cervicitis, 10 cervical intraepithelial neoplasias (CIN I: 3 In the current study we examined the presence of point mutations in codon 12 of K-, H-and N-ras genes and performed detection and distinction of the human papillomavirus in 112 cases of genital lesions.
Sixteen out of the 112 samples were found to carry a point mutation in codon 12 of K-ras (Fig. 2) , 9 of H-ras (Fig.  3) , while only 4 of N-ras gene (Fig. 4) . Our study was limited to codon 12 of the K-ras gene, since mutations preferentially occur at this codon (25) . The K-ras mutations were found in 2 out of 37 (5.4%) patients with cervicitis, in 1 out of 10 (10%) with CIN II, in 2 out of 7 (28.6%) with well differentiated cervical adenocarcinoma, in 1 patient with in situ squamous cell carcinoma, in 7 out of 29 (24.1%) with squamous cell carcinoma of the cervix (6 cases of moderately and 1 case of poorly differentiated), in 1 patient with moderately differentiated mucoepidermoid carcinoma of the cervix, in 1 out of 14 (7.1%) with a moderately differentiated endometrial adenocarcinoma and 1 out of 5 (20%) patients with a poorly differentiated ovarian adenocarcinoma. The Hras mutations were found in 2 out of 37 (5.4%) patients with cervicitis, in 2 out of 10 (20%) with CIN II and CIN III, in 1 out of 7 (14.3%) with a well differentiated cervical adenocarcinoma, in 2 out of 31 (6.5%) with moderately differentiated squamous cell cervical carcinoma and in 2 out of 14 (14.3%) with moderately differentiated endometrial adenocarcinoma. The N-ras mutations were found in 1 out of 37 (2.7%) patients with cervicitis, in 1 patient of in situ squamous cell carcinoma of the cervix and in 2 out of 29 (6.9%) patients with squamous cell cervical carcinoma (1 case well and 1 case moderately differentiated). Fifty-eight out of the 112 genital lesions were found positive for HPV (Figs. 5 and 6) with the highest incidence occuring in squamous cell carcinomas of the cervix (79.3%) while in intraepithelial and benign lesions of the cervix, the incidence was lower (70.0% and 40.5% respectively, p=0.001). The results of PCR analysis of the 112 samples are summarized in Table I .
K-ras mutations and HPV were more frequently found in malignant lesions of the cervix (28.2% and 76.9% respectively) than in benign (5.4% and 40.5% respectively, p<0.008), while in malignant cervical lesions with K-ras mutations, HPV was often detected in the same sample (25.6% vs 2.7%, p=0.004). The highest incidence of K-ras mutations was observed in squamous cell carcinomas of the cervix (24.1%), while K-ras mutations also occured in cases of cervicitis (5.4%). A comparative analysis between benign and malignant lesions of the cervix is shown in Table II ,a. Results from the type distinction of HPV indicated that HPV 18 was the most frequent type (with an incidence of 30.2%) while HPV 16 was found at a lower rate (27.9%). HPV6 was not detected in any lesion, while HPV 11 was more prevalent in benign lesions, often as a co-infection with HPV 18 (Table II,b) .
Correlation between the presence of ras mutations and HPV with the histological differentiation of cervical tumors is summarized in Table III . The frequency of ras mutations was related to histological differentiation of the tumor, since it was higher in well differentiated (50%) than in moderately differentiated tumors (8%, p=0.011), although the stage was not available for all the tumors. The rate of HPV DNA detection was more frequent in patients with poorly differentiated (85.7%) than in patients with moderately or well differentiated tumors (44% and 33% respectively, p<0.059).
Discussion
The multi-event nature of carcinogenesis has led to extensive studies of oncogenes, onco-suppressor genes and viral factors involved in animal and human cancers. The collaboration of ras oncogene with HPV E6/E7 genes in inducing full transformation of cervical keratinocytes has been well documented (13, 14) . However the exact role of the ras oncogene in human carcinogenesis is not yet clear, despite the fact that ras mutations occur with variable frequency in a wide variety of tumors (26) . Previous studies have shown that the incidence of ras mutations in cervical carcinomas is low (11, 18) . The frequency found in the current study for K-ras mutations was significantly higher in malignant cervical lesions (28.2%) than in benign precursors (5.4%, p=0.008). The frequency of ras mutations was higher in well than in moderately differentiated tumors, while no mutations were (18) (19) (20) . Although there are reports on codon 12 point mutations of K-ras, none exists in Η-ras gene.
Variations in the prevalence of HPV types in cervical lesions have been found and attributed to geographical differences, focal heterogeneity of HPV replication within lesions sampled, or variability in the sensitivity of the assays employed (24) . In areas with high-incidence of cervical cancer there seems to be little difference in the prevalence of HPV 16 and HPV 18, whereas in areas with moderately-high incidence, HPV 16 is more common than HPV 18 (27) . In the current study we found a higher rate of infection by HPV 18 (30.2%) compared to HPV 16 (27.9%) in the 86 cervical lesions examined. HPV 18 infection was more commonly associated with poorer histological differentiation and our results are substantiated with previous observations that HPV 18 confers greater aggression than HPV 16 and has been associated with a more rapid progression to malignancy (28) . In addition in vivo and in vitro studies have often indicated that HPV 18 is more effective in immortalization and transformation than HPV 16 (29) .
The simultaneous presence of ras mutations and high risk HPV DNA was detected in 10 cases. Its significance is not known, but it has been shown that in vitro E6-E7 immortalized primary human epidermal keratinocytes can be rendered malignant after additional transfection with v-ras oncogene, while W-ras can overcome the anti-proliferative and anti-transformation effects of wild-type p53 in NIH3T3 cells (13) (14) (15) . Since the simultaneous presence of HPV and K-ras mutations was more frequently detected in malignant cervical lesions (25.6%) than in benign (2.7%, p=0.004), a cooperation between them in neoplastic change is suggested.
These experiments support a multistep process for malignant conversion, since for tumors that do not contain any detectable ras mutation alternative genetic alterations are presumed. The availability of human epithelial cell transformation model should facilitate studies of the interaction between HPV and human epithelial cells, ras activation combined with HPV infection may be an important step in substantial numbers of cervical carcinomas, while their interaction with other genes or events may also be involved.
